CK7 antibodies are pivotal in tumor classification and metastatic origin determination:
CK7 expression patterns and clinical outcomes have been extensively studied:
Key Observations:
CK7+ CRCs exhibit dedifferentiation, tumor budding, and micropapillary patterns .
Prognostic relevance persists even in multivariate analysis, independent of stage or grade .
Non-small cell lung cancer (NSCLC): Adenocarcinoma subtypes show CK7+ expression, while squamous cell carcinomas may be CK7- .
Small cell lung cancer (SCLC): Rare CK7+ cases, but limited data .
Breast Cancer: CK7+ in ductal carcinomas; CK7- in lobular carcinomas .
Urothelial Carcinomas: CK7+ correlates with poor prognosis in some studies .
Antibody | Strengths | Limitations |
---|---|---|
RM284 (Rabbit) | High specificity, validated in FFPE tissues | Limited species reactivity (human only) |
EPR17078 (Rabbit) | Broad species compatibility (human/mouse/rat), batch consistency | Higher cost due to recombinant production |
OV-TL12/30 (Mouse) | Low cross-reactivity, widely used in IHC | Requires optimization for WB |
Polyclonal (NBP1-33104) | Broad epitope recognition | Lower specificity, background staining |